Eli Lilly and Company (LLY)
$1179.27+0.83%Close
BUYRECOVERY · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV21.6%–69.8%
- Market cap
- $1.1T
- Beta
- 0.45
- Div yield
- 0.58%
- P/E (TTM)
- 38.72
- IV-%ile
- 45
- IV ATM
- 34.0%
- Short % float
- 0.83%
- Days to cover
- 2.9
- SI change
- -6.4%
- 1W
- +3.19%
- 1M
- +5.01%
- vs SPY 1W
- +2.03%
- vs SPY 1M
- +2.01%
Industry peers
FMP comparable companies · ranked by market cap
- JNJSELLJohnson & Johnson$618.1BBEARQ 22$256.48+1.93%
- ABBVBUYAbbVie Inc.$481.3BBULLQ 29$272.42+1.49%
- MRKSELLMerck & Co., Inc.$351.7BBEARQ 11$142.40+2.26%
- RHHBYRoche Holding AG$340.1B$53.36
- NVSBUYNovartis AG$272.0BRECOVERYQ 20$143.11+0.45%
- AZNSELLAstraZeneca PLC$246.2BRECOVERYQ 20$158.78+0.26%
- AMGNBUYAmgen Inc.$219.9BRECOVERYQ 22$407.44+1.82%
- NVOSELLNovo Nordisk A/S$169.5BRECOVERYQ 20$38.18+1.20%
- PFESELLPfizer Inc.$158.6BBULLQ 13$27.82+1.65%
- SNYSELLSanofi$96.6BBEARQ 11$40.23-0.40%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on LLY?
- LOPJLB’s latest quantitative signal on Eli Lilly and Company (LLY) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is LLY in?
- Eli Lilly and Company (LLY) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Eli Lilly and Company (LLY) do?
- Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (incl…